Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Eli Lilly and Company LILLY CORPORATE CENTER INDIANAPOLIS IN 46285 USA

www.lilly.com Employees: 47,000 P: 317-276-2000

Sector:

Medical

Description:

Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.

Key Statistics

Overview:

Market Capitalization, $K 745,792,384
Enterprise Value, $K 771,051,072
Shares Outstanding, K 947,736
Annual Sales, $ 45,043 M
Annual Net Income, $ 10,590 M
Last Quarter Sales, $ 12,729 M
Last Quarter Net Income, $ 2,759 M
EBIT, $ 14,085 M
EBITDA, $ 15,852 M
60-Month Beta 0.40
% of Insider Shareholders 0.13%
% of Institutional Shareholders 82.53%
Float, K 946,504
% Float 99.87%
Short Volume Ratio 0.40

Growth:

1-Year Return -15.87%
3-Year Return 138.43%
5-Year Return 376.41%
5-Year Revenue Growth 101.81%
5-Year Earnings Growth 115.07%
5-Year Dividend Growth 101.55%

Per-Share Information:

Most Recent Earnings 3.34 on 05/01/25
Next Earnings Date 08/07/25 [BMO]
Earnings Per Share ttm 13.76
EPS Growth vs. Prev Qtr -37.22%
EPS Growth vs. Prev Year 29.46%
Annual Dividend Rate, $ 5.60
Annual Dividend Yield 0.71%
Most Recent Dividend 1.500 on 05/16/25
Next Ex-Dividends Date 08/15/25
Dividend Payable Date 09/10/25
Dividend Payout Ratio 41.28%
Most Recent Split 2-1 on 10/16/97

LLY Ratios

Ratio
Price/Earnings ttm 56.52
Price/Earnings forward 35.45
Price/Earnings to Growth 1.14
Return-on-Equity % 85.51%
Return-on-Assets % 15.74%
Profit Margin % 23.51%
Debt/Equity 2.18
Price/Sales 16.36
Price/Cash Flow 54.63
Price/Book 46.51
Book Value/Share 16.72
Interest Coverage 2.34

LLY Dividends

Date Value
05/16/25 $1.5000
02/14/25 $1.5000
11/15/24 $1.3000
08/15/24 $1.3000
05/15/24 $1.3000
02/14/24 $1.3000
11/14/23 $1.1300
08/14/23 $1.1300
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar